Identifying candidates with promising ADME and pharmacokinetics properties during the discovery phase of drug development lays the groundwork for future clinical trials and regulatory approval. However, translating a long-term study into a successful outcome requires reliable, qualified measurements at a clinical scale.

Q² Solutions’ global bioanalytical services network brings substantial expertise in biomarker assays and cell-based bioanalytical assays that target multi-domain proteins, antibodies, oligonucleotides, antibody-drug conjugates, and peptides.

Specific strengths include:

• ADME assay development (including drug-drug interaction testing, discovery and development metabolite identification, and in vitro ADME screening)
• Ligand-binding assays
• Pharmacokinetic (PK) testing
• Immunogenicity testing and immunoassays
• Biomarker assays
• Large molecule bioanalysis and LC/MS bioanalysis
• DMPK services